Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ExonHit launches Alzheimer's blood test for research use

This article was originally published in Clinica

Executive Summary

ExonHit Therapeutics has launched its Alzheimer’s blood test, AclarusDx. The product is now available for research use only for pharmaceutical companies and academic centres conducting clinical trials in the disorder. ExonHit (Paris, France) will process blood samples at its GLP-compliant labs in the US. The company plans to CE mark the test for sale in Europe in the fourth quarter of 2010, with a European launch following in the first quarter of 2011. AclarusDx analyses whether messenger RNA from a patient's blood sample matches a molecular profile that is specific to Alzheimer's disease.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT044898

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel